{"schema_version":"1.0","type":"article","title":"半年千億，買的是時間","url":"https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time.md","lang":"zh-Hant","date":"2026-07-27","publish_at":"2026-07-27T08:00:00+08:00","updated_at":"2026-07-27","category":"商業分析系列","topic":"商業分析系列","tags":["生技併購","藥廠併購","Biopharma M&A","專利懸崖","Lilly","Merck","AbbVie","Gilead","GSK","Terns","Apogee","Arcellx","Tubulis","Nuvalent","Organon","CVR","里程碑"],"summary":"2026 上半年生醫併購轉熱，但 BioSpace 的 52 筆與 IQVIA 的 42 筆不能硬拼。真正的主線，是專利懸崖迫使大藥廠用現金購買可計算的臨床時間。","key_points":[],"facts":[],"sections":["52 筆和 42 筆，差的不是 10 筆而已","藥廠買的不是故事，是專利時鐘","禮來掃貨，但不是原文寫的 11 筆","吉利德與 GSK，押的是接近商業化的腫瘤資產","最大一筆，也不能只看 headline 數字","併購熱，為什麼不等於 Biotech 寒冬結束？","台灣讀者該看什麼？","結語：半年千億，買的是時間","參考資料","免責聲明"],"references":[{"title":"查證截止：2026-07-19。","source":"","date":"","url":""},{"title":"[BioSpace","source":"H1 2026 M&A count and methodology]","date":"","url":"https://www.biospace.com/business/biopharma-strikes-50-m-as-deals-in-h1-led-by-lillys-25b-spend"},{"title":"[IQVIA","source":"Biopharma M&A: Mid-year 2026 update]","date":"","url":"https://www.iqvia.com/locations/emea/blogs/2026/07/biopharma-ma-mid-year-2026-update"},{"title":"[PwC","source":"US Deals 2026 midyear outlook]","date":"","url":"https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html"},{"title":"[Merck／Terns","source":"Transaction agreement]","date":"","url":"https://www.merck.com/news/merck-to-acquire-terns-pharmaceuticals-inc-expanding-its-hematology-pipeline-with-tern-701-a-novel-candidate-for-chronic-myeloid-leukemia-cml/"},{"title":"[Merck","source":"Completion of Terns acquisition]","date":"","url":"https://www.merck.com/news/merck-completes-acquisition-of-terns-pharmaceuticals-inc/"},{"title":"[AbbVie／Apogee","source":"Transaction announcement]","date":"","url":"https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-apogee-therapeutics-deepening-immunology"},{"title":"[Gilead","source":"Completion of Arcellx acquisition]","date":"","url":"https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel"},{"title":"[Gilead","source":"Completion of Tubulis acquisition]","date":"","url":"https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-Completes-Acquisition-of-Tubulis-Further-Strengthening-Oncology-Portfolio/default.aspx"},{"title":"[GSK／Nuvalent","source":"Transaction agreement]","date":"","url":"https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-nuvalent-inc/"},{"title":"[GSK","source":"Completion of Nuvalent acquisition]","date":"","url":"https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-nuvalent-inc/"},{"title":"[Sun Pharma／Organon","source":"Definitive agreement]","date":"","url":"https://www.organon.com/news/sun-pharma-signs-definitive-agreement-to-acquire-organon/"}],"images":[{"alt":"BioSpace 與 IQVIA 的統計口徑不同，52 筆與 42 筆不能直接相加","url":"https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time/01_%E5%85%A9%E5%80%8B%E7%B5%B1%E8%A8%88%E4%B8%8D%E8%83%BD%E7%A1%AC%E6%8B%BC.webp"},{"alt":"專利懸崖迫使大型藥廠以更高價格購買接近讀出、申請或上市的時間","url":"https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time/02_%E5%B0%88%E5%88%A9%E6%87%B8%E5%B4%96%E8%B2%B7%E6%99%82%E9%96%93.webp"},{"alt":"六筆代表交易分別處於宣布、完成、早期臨床、FDA 審查與等待交割等不同狀態","url":"https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time/03_%E5%85%AD%E7%AD%86%E4%BA%A4%E6%98%93%E7%8B%80%E6%85%8B.webp"},{"alt":"前期現金、里程碑、CVR 與交割條件把併購風險分配給不同參與者","url":"https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time/04_%E4%BA%A4%E6%98%93%E6%A2%9D%E6%AC%BE%E5%88%86%E9%85%8D%E9%A2%A8%E9%9A%AA.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time/cover-zh.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-27）。半年千億，買的是時間。https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-07-27-h1-2026-biopharma-ma-buying-time-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}